暂无数据
代码股票名称
最新价涨跌额涨跌幅成交量成交额今开昨收最高最低总市值流通市值总股本流通股本5日涨跌幅10日涨跌幅20日涨跌幅60日涨跌幅120日涨跌幅250日涨跌幅年初至今涨跌幅股息率TTM换手率市盈率TTM市盈率(静)振幅所属行业
美股市场个股详情
NVS 诺华制药
- 103.105
- -0.205-0.20%
交易中 05/15 15:04 (美东)
2103.76亿总市值14.07市盈率TTM
103.550最高价103.020最低价70.76万股成交量103.250今开103.310昨收7309.04万成交额0.04%换手率14.52市盈率(静)20.40亿总股本104.81652周最高5.30市净率2009.60亿流通值85.72652周最低3.78股息TTM19.49亿流通股104.816历史最高3.66%股息率TTM0.51%振幅7.088历史最低103.288平均价1股每手
盘中分时
- 5日
- 日K
- 周K
- 月K
- 季K
- 年K
资金分布
单位: --
资金流向
实时日周月
暂无数据
新闻
继季度表现之后，Voyager Therapeutics上涨
低价交易的欧洲买入评级股票 Vs.他们的美国同行-瑞银
快讯 | 纽约证券交易所订单不平衡 64369.0 股卖出方
由于前列腺癌试验结果令人失望，MacroGenics被降级：“我们对报告的死亡感到惊讶”
MacroGenics Inc（纳斯达克股票代码：MGNX）发布了TAMARACK对vobramitamab duocarmazine（vobra duo）的2期研究（vobra duo）的中期数据。TAMARACK正在对先前接受过治疗的转移患者进行
快讯 | 诺华获得 FDA 对 Scemblix 的突破性称号
快讯 | 纽约证券交易所订单失衡 55282.0 股卖方股票
评论
Stories you might have missed ![]()
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
7
Google's disappointing ad sales growth and AMD's lower revenue guidance have hurt investor sentiment, causing their shares to drop. Byron Allen's offer to acquire Paramount Global is seen as beneficial for shareholders, boosting its share price. Novartis AG's lower Q4 earnings and adjusted mid-term guidance have led to a share price decline.
JPMorgan analysts predict a strong uptake for Novartis's various treatments to boost the company's top line, with cost savings from restructuring aiding the bottom line. Morgan Stanley analysts note Novartis's need for external innovation to meet long-term growth ambitions.
Recent M&A activities💰 in January:
$Ambrx Biopharma(AMAM.US$ acquisition by $强生(JNJ.US$
Aiolos Bio acquisition by $葛兰素史克(GSK.US$
$Harpoon Therapeutics(HARP.US$ acquisition by $默沙东(MRK.US$
Calypso Biotech acquisition by $诺华制药(NVS.US$
What companies will be next? 🤔
$Ambrx Biopharma(AMAM.US$ acquisition by $强生(JNJ.US$
Aiolos Bio acquisition by $葛兰素史克(GSK.US$
$Harpoon Therapeutics(HARP.US$ acquisition by $默沙东(MRK.US$
Calypso Biotech acquisition by $诺华制药(NVS.US$
What companies will be next? 🤔
1
Since last October, the biotech sector has been showing signs of recovery. This trend was underscored by the S&P Biotechnology Select Industry Index, which surged by 4.69% yesterday and jumped to a new high since Aug 2022.On 8 Jan, J&J, Merck, and Novartis each announced a series of acquisition deals, many of which featured premiums of over 100%:
● $强生(JNJ.US$ has agreed to pay $2 billion in cash for antib...
● $强生(JNJ.US$ has agreed to pay $2 billion in cash for antib...
10
阅读更多
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅
